key: cord-0773923-8lzpz58y
authors: Jolliffe, D.; Holt, H.; Greenig, M.; Talaei, M.; Perdek, N.; Pfeffer, P.; Maltby, S.; Symons, J.; Barlow, N.; Normandale, A.; Garcha, R.; Richter, A.; Faustini, S.; Orton, C.; Ford, D.; Lyons, R.; Davies, G.; Kee, F.; Griffiths, C.; Norrie, J.; Sheikh, A.; Shaheen, S.; Relton, C.; Martineau, A.
title: Vitamin D Supplements for Prevention of Covid-19 or other Acute Respiratory Infections: a Phase 3 Randomized Controlled Trial (CORONAVIT)
date: 2022-03-23
journal: nan
DOI: 10.1101/2022.03.22.22271707
sha: 2630443f4e7c4c4515afcbadf3f76e5dbc21eeeb
doc_id: 773923
cord_uid: 8lzpz58y

BACKGROUND: Vitamin D metabolites support innate immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory pathogens. Randomized controlled trials of vitamin D to prevent coronavirus disease 2019 (Covid-19) have not yet reported. METHODS: We randomly assigned 6200 U.K. adults to receive an offer of a postal finger-prick 25-hydroxyvitamin D (25[OH]D) test with provision of a 6-month supply of higher-dose vitamin D (3200 IU/d, n=1550) or lower-dose vitamin D (800 IU/d, n=1550) to those with blood 25(OH)D concentration <75 nmol/L, vs. no offer of testing or supplementation (n=3100). The primary outcome was the proportion of participants experiencing at least one swab test- or doctor-confirmed acute respiratory infection (ARI) of any cause at six months. Secondary outcomes included incidence of swab test-confirmed Covid-19. RESULTS: Of 3100 participants offered testing, 2958 (95.4%) accepted, and 2690 (86.8%) had 25(OH)D <75 nmol/L and were sent vitamin D supplements (1356 higher-dose, 1334 lower-dose). 76 (5.0%) vs. 87 (5.7%) vs. 136 (4.6%) participants in higher-dose vs. lower-dose vs. no-offer groups experienced at least one ARI of any cause (odds ratio [OR] for higher-dose vs. no-offer 1.09, 95% CI 0.82-1.46; lower-dose vs. no-offer 1.26, 0.96-1.66). 45 (3.0%) vs. 55 (3.6%) vs. 78 (2.6%) participants in higher-dose vs. lower-dose vs. no-offer groups developed Covid-19 (OR for higher-dose vs. no-offer 1.13, 0.78-1.63; lower-dose vs. no-offer 1.39, 0.98-1.97). CONCLUSIONS: Among adults with a high baseline prevalence of vitamin D insufficiency, implementation of a test-and-treat approach to vitamin D replacement did not reduce risk of all-cause ARI or Covid-19.

The coronavirus disease 2019 (Covid-19) pandemic has refocused attention on strategies to prevent acute respiratory infection (ARI). Although vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents the mainstay for disease control, its effectiveness at a global level is compromised by factors including cost, availability, vaccine hesitancy, vaccine failure and vaccine escape. [1] [2] [3] Complementary, low-cost approaches to enhance immunity to SARS-CoV-2 and other pathogens causing ARI are needed.

Vitamin D metabolites have long been recognized to support diverse innate immune responses to respiratory viruses and bacteria, while simultaneously regulating immunopathological inflammation. [4] [5] [6] The vitamin D-inducible antimicrobial peptides cathelicidin LL-37 and human beta defensin 2 have both been shown to bind SARS-CoV-2 spike protein and inhibit binding to Angiotensin Converting Enzyme 2, its cellular receptor. 7, 8 Longitudinal studies investigating potential associations between higher vitamin D status or vitamin D supplement use and reduced risk of Covid-19 or SARS-CoV-2 infection have yielded mixed results, with some reporting protective associations and others reporting null or negative associations; 9-14 meta-analyses including these and other observational studies report protective associations overall. 15, 16 Findings of randomized controlled trials (RCTs) of vitamin D supplementation to prevent ARIs caused by pathogens other than SARS-CoV-2 have also been heterogeneous. [17] [18] [19] [20] [21] Meta-analysis of these and other RCTs shows a small, but statistically significant, protective effect that is strongest where modest daily doses of vitamin D (400-1000 IU) are given for periods of up to one year. 22 Phase 3 clinical trials of prophylactic vitamin D to reduce incidence and severity of Covid-19 are lacking, as are studies comparing effectiveness of different doses of vitamin D supplementation for the prevention of ARIs of any cause among adults.

There is also a lack of studies designed to evaluate the effectiveness of practical approaches to identification and treatment of vitamin D deficiency at scale in the general population to improve health outcomes. We therefore established a Phase 3 pragmatic RCT (CORONAVIT) to evaluate the effectiveness of a 'test-and-treat' approach to identification and treatment of vitamin D insufficiency for prevention of Covid-19 and other ARIs in U.K. adults from December 2020 to June 2021 -a period when Covid-19 incidence was high and Covid-19 vaccine coverage was initially low.

We conducted a three-arm parallel open-label individually-randomized controlled trial nested within the population-based COVIDENCE UK cohort study, 12, 13 using 'trialwithin-cohort' methodology. 23 Eligibility was assessed using self-reported data from on-line questionnaires. Principal inclusion criteria were age 16 years or more at screening and participation in the COVIDENCE UK cohort; principal exclusion criteria were current use of vitamin D supplements, known diagnosis of sarcoidosis, primary hyperparathyroidism, nephrolithiasis, or renal failure requiring dialysis; known allergy to any ingredient in the study capsules; and known pregnancy.

A randomly-selected subset of 6200 cohort participants who were assessed as eligible on the basis of data from their enrolment questionnaire, and who reported no supplemental vitamin D intake at baseline, were individually randomized by the trial statistician using a computer program (Stata v14.2) to receive an offer of a postal vitamin D test with supply of 3200 IU vitamin D/day if their blood 25(OH)D concentration was found to be less than 75 nmol/L ('higher-dose offer group') vs. the same testing offer with supply of 800 IU vitamin D/day if 25(OH)D was less than 75 nmol/L ('lower-dose offer group') vs. no offer of vitamin D testing or supplementation ('no offer group'), with a 1:1:2 allocation ratio. Treatment allocation was not concealed.

Study participants were invited to complete follow-up on-line questionnaires at monthly intervals, which captured details of incident ARIs, exacerbations of asthma 6 and chronic obstructive pulmonary disease (COPD), chronic Covid-19 symptoms, adherence, and adverse events. The final invitation to complete a follow-up questionnaire was sent in June 2021, at 6-month follow-up. End-trial postal vitamin D testing was offered to a randomly selected subset of 1600 participants who received study supplements (800 in each offer group) and 400 cohort participants who were randomized to the no offer group.

The primary outcome was the proportion of participants developing at least one swab test-or doctor-confirmed ARI of any cause. Secondary efficacy outcomes were the proportion of all participants developing Covid-19 confirmed by reverse transcription polymerase chain reaction (RT-PCR) or antigen testing; the proportion of all participants hospitalized for treatment of Covid-19; the proportion of participants hospitalized for treatment of Covid-19 who required ventilatory support; the proportion of all participants dying of Covid-19; the proportion of participants developing test-confirmed Covid-19 who reported symptoms lasting more than four weeks; the proportion of participants developing test-confirmed Covid-19 who reported on-going symptoms at the end of the study; mean values for the MRC dyspnea score 24 , the FACIT Fatigue Scale score 25 and the Post-Covid Physical Health Symptom Score 26 among participants developing test-confirmed Covid-19 who reported on-going symptoms at the end of the study; the proportion of all participants prescribed one or more courses of antibiotics for treatment of ARI of any cause; the proportion of all participants hospitalized for treatment of ARI of any cause; the proportion of all participants dying of ARI of any cause; the proportion of participants with asthma or COPD developing at least one severe acute exacerbation; and mean end-study 25(OH)D concentrations in the sub-set of participants for whom this was measured.

Safety outcomes were incidence of death, serious adverse events, adverse events leading to discontinuation of study medication, and other monitored safety conditions: hypercalcemia (serum corrected calcium concentration >2.65 mmol/L), hypervitaminosis D (25[OH]D concentration >220 nmol/L) and nephrolithiasis.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

We used https://mjgrayling.shinyapps.io/multiarm/ 27 to calculate that a total of 6200 participants would need to be randomized to detect a 20% reduction in the proportion of participants meeting the primary outcome with 84% marginal power 28 and 5% type 1 error rate, assuming a 20% risk of experiencing at least one swab test-or doctor-confirmed ARI in the no offer group at six months, 25% loss to followup, and a 1:1:2 ratio of participants randomized to higher-dose, lower-dose or no offer, respectively. Statistical analyses were performed according to intention-totreat; adjustment for multiple testing for the primary outcome used Dunnett's test 29 with a critical P-value threshold of 0.027. Treatment effects for dichotomous outcomes were estimated using logistic regression and presented as odds ratios (ORs) with 95% confidence intervals (CIs). We pre-specified sub-group analyses comparing the effect of the intervention on major outcomes in individuals who received at least one dose of Covid-19 vaccine during follow-up vs. those who did not, and in those with lower vs. higher actual or predicted baseline 25(OH)D concentrations. A sensitivity analysis was also pre-specified, which excluded data from participants in the intervention arms who reported that they took vitamin D capsules 'less than half the time' as well as those in the no offer arm who reported any intake of supplemental vitamin D during follow-up. Further details of statistical methods are presented in the Supplementary Appendix.

A total of 17700 participants in the COVIDENCE UK cohort study were assessed for eligibility to take part in the CORONAVIT trial in October 2020: 6200 of 6470 participants classified as eligible based on their responses to study questionnaires were randomly selected for invitation to the trial, and randomly assigned to higherdose vs. lower-dose vs. no offer groups (Fig. 1) . Table 1 shows baseline characteristics of the trial participants by study arm. Median age was 60.2 years, 4156/6200 (67.0%) were female and 154/6200 (2.5%) had received one or more . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) No statistically significant differences in outcomes relating to incidence or severity of acute Covid-19, prolonged symptoms of Covid-19 were seen between those randomized to either offer vs. no offer ( Table 2) . We also found no evidence to suggest that allocation to either offer vs. no offer influenced prescription of antibiotics for ARI treatment, hospitalization or death from all-cause ARI, or incidence of acute exacerbations of asthma or COPD (Table 2) .

Sub-group analysis revealed no evidence to suggest that Covid-19 vaccination modified the effect of allocation on incidence of Covid-19 or prolonged Covid-19 symptoms (Table S2, 

Of 3100 people randomized to the no offer group, 1547 (49.9%) reported that they took supplemental vitamin D on at least one occasion during the study, while 2523/2674 (94.4%) participants supplied with study supplements reported that they took them more than half the time. Results of sensitivity analyses excluding the former group and including the latter (Table 3) were not materially different to those yielded by intention to treat analyses ( study supplements were discontinued, and the hypercalcemia and symptoms resolved. One participant in the no offer group was found to have asymptomatic hypervitaminosis D (25[OH]D 250 nmol/L) at 6-month follow-up, after taking a nonstudy vitamin D supplement at a dose of 4000 IU/day. One participant in the higher dose offer group was hospitalized on two occasions with renal colic due to nephrolithiasis. A total of 47 non-severe adverse events led to discontinuation of study supplements (24 vs. 23 in higher-vs. lower-dose offer groups, respectively: 

We present results of the first RCT to evaluate the effectiveness of a test-and-treat approach to correction of sub-optimal vitamin D status for prevention of ARIs. It is also the first clinical trial to investigate whether vitamin D supplementation reduces risk of Covid-19. Among participants randomized to receive an offer of vitamin D testing, uptake of this intervention was good, prevalence of 25(OH)D concentrations <75 nmol/L was high, and end-study 25(OH)D concentrations were elevated when compared to those who were randomized to no such offer, providing objective evidence of a high level of adherence. However, no statistically significant effect of either dose was seen on the primary outcome of incident doctor-or swab testconfirmed ARI, or on the major secondary outcome of incident swab test-confirmed Covid-19. Oral vitamin D supplementation was safe and well-tolerated at both doses investigated: incidence of adverse events was balanced between arms, and no serious adverse event was attributed to study supplements.

The design of our study was informed by findings from a recent meta-analysis, suggesting that protective effects of vitamin D against ARI might be strongest when daily doses of 400-1000 IU were given for up to one year. 22 The results from the current study do not support the hypothesis that such regimens offer protection . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 23, 2022.

against ARI, and are consistent with those of several other recent phase 3 trials of vitamin D supplementation that have reported no effect of vitamin D supplementation on risk of ARIs. 20,21,30 The null result for the major secondary outcome of incident Covid-19 in this trial is consistent with our finding of no independent association between intake of supplemental vitamin D and risk of Covid-19 in a prospective observational study undertaken in this cohort prior to initiation of this trial, 12 as well as null results from a Mendelian randomization study that tested for associations between genetically predicted 25(OH)D concentrations and susceptibility to Covid-19. 31 Positive findings from other observational studies 9,14 may therefore be attributable to confounding or collider bias. 32

Our study has several strengths. In contrast to recent large clinical trials of vitamin D supplementation for the prevention of ARIs, 21,30 our study population had a very high prevalence of vitamin D insufficiency at baseline, with 97.4% of those tested having 25(OH)D concentrations <75 nmol/L. We investigated two dosing regimens utilizing daily dosing (thereby avoiding large and unphysiologic fluctuations in 25[OH]D that are seen with administration of intermittent bolus dosing), 33 and there was good adherence (evidenced by self-report and by significant differences in end-study 25[OH]D concentrations between arms). The trial within cohort design allowed a rapid and efficient evaluation of a pragmatic approach to boosting vitamin D status in the general population to provide a timely answer to a pressing global public health question. Linkage with routinely collected data from medical records allowed comprehensive capture of outcomes in those who did not complete study questionnaires, allowing us to minimize loss to follow-up and to capture important events that precluded questionnaire completion such as severe illness and death.

The trial was initiated prior to widespread roll-out of Covid-19 vaccination, and followup coincided with the 'second wave' of Covid-19 in the UK: both factors contributed to the appreciable number of Covid-19 cases that arose, which allowed for potential effects of vitamin D on prevention of this specific cause of ARI to be investigated.

Other strengths include a high retention rate (just 0.6% of participants withdrew without any follow-up), a rigorous case definition for the primary outcome that required objective confirmation of ARI (as opposed to self-report of symptoms), and use of an externally accredited laboratory to measure vitamin D status using liquid . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.22.22271707 doi: medRxiv preprint chromatography-tandem mass spectrometry, which is the gold standard assay for this determination.

Our study also has limitations. Provision of supplements to participants randomized to intervention was contingent on demonstrating inadequate vitamin D status: thus, a subset (13.7%) of participants randomized to intervention did not receive study supplements. On the other hand, another subset (49.9%) of participants randomized to no offer took a vitamin D supplement on one or more occasions during follow-up.

This may have led to increases in 25(OH)D concentrations in the no offer arm over the course of the study, although seasonal effects (sampling in June vs. December) will also have contributed. Together, these factors could have diluted any effect of vitamin D in the primary intention-to-treat analysis. We sought to overcome this by conducting a sensitivity analysis, which included only those randomized to offer vs. no offer who did vs. did not take supplemental vitamin D, respectively. The fact that this analysis showed no effect of vitamin D supplementation on all outcomes investigated, despite the larger differences in end-study 25(OH)D concentrations between intervention vs. no-offer arms seen for this analysis vs. the intention-to-treat analysis ( Fig. 2) , provides some reassurance that the null result yielded by the intention-to-treat analysis is valid. Ultimately, however, this trial was designed to investigate the effectiveness of a pragmatic 'test-and-treat' approach to boosting population vitamin D status, rather than biologic efficacy of vitamin D to prevent ARIs, and our findings should be interpreted accordingly. Ascertainment bias could have arisen because of the open-label design since knowledge of allocation could have influenced retention and the likelihood of an outcome being reported. We attempted to off-set effects of differential rates of loss to follow-up between arms by use of medical record linkage, which allowed us to capture outcomes in those who were lost to follow-up but who did not actively withdraw from the study. The proportion of those randomized to 'no offer' who experienced the primary outcome (4.6%) was lower than the 20% anticipated in the sample size calculation, possibly reflecting the impact of public health measures to control transmission of SARS-CoV-2 (such as lockdowns, social distancing and mask wearing) on incidence of other ARIs. 34 This could have compromised power; however, the lower bounds for the 95% CIs of ORs relating to the effect of higher-or lower-dose offers on our primary outcome (0.82 and 0.96, respectively) effectively rule out relative reductions . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 23, 2022. ;  in odds of ARI of more than 18% and 4%, respectively. Arguably, effects of this size or less are unlikely to be considered of sufficient magnitude to implement the study intervention for the purpose of ARI prevention. Incidence of hospitalization for ARI was low, and we therefore lacked power to detect an effect of the intervention on severity of Covid-19 and other ARIs. Finally, prevalence of profound vitamin D deficiency (25[OH]D <25 nmol/L) at baseline was also low, and we therefore lacked power to detect an effect of the intervention in this group, who may be more likely to derive clinical benefit from vitamin D replacement than those with higher baseline 25(OH)D concentrations. 35

In conclusion, we report that implementation of a test-and-treat approach to correcting sub-optimal vitamin D status in the U.K. population was safe and effective in boosting 25(OH)D concentrations of adults with baseline concentrations <75 nmol/L. However, this was not associated with protection against all-cause ARI or Covid-19. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

< 2 5 . 0 - -( 2 )2 1 6 ( 1 3 . 9 ) 2 3 2 ( 1 5 . 0 ) - -( 2 )2 5 . 0 - 4 9 . 9 - -( 2 )7 9 7 ( 5 1 . 4 ) 7 5 9 ( 4 9 . 0 ) - - ( 2 ) 5 0 - 7 4 . 9 - -( 2 )3 3 3 ( 2 1 . 5 ) 3 3 7 ( 2 1 . 7 ) - - ( 2 ) ≥ 7 5 . 0 - - ( 2 ) 2 8 ( 1 . 8 ) 4 3 ( 2 . 7 ) - - ( 2 ) N o t d e t e r m i n e d - -( 2 )1 7 6 ( 1 1 . 4 ) 1 7 9 ( 1 1 . 6 ) 3 1 0 0 ( 1 0 0 . 0 ) A b b r e v i1 7 % ( 1 / 2 4 ) 2 . 5 0 % ( 1 / 4 0 ) 1 . 3 9 ( 0 . 0 8 , 2 3 . 2 3 ) 0 . 8 2 - - - - 1 . 7 0 ( 0 . 1 0 , 2 8 . 4 3 ) 0 . 7 1 - - - - P r o p o r t i o n o f a l l p a r t i c i p a n t s d y i n g o f C o v i d - 1 9 ( % ) 0 . 0 0 % ( 0 / 1 5 1 5 ) 0 . 0 0 % ( 0 / 1 5 1 5 ) 0 . 0 0 % ( 0 / 2 9 4 9 ) - - 4 - - - - - - - - 4 - - - - 4 - - ' L o n g C o v i d ' o u t0 . 0 0 % ( 0 / 1 5 1 5 ) 0 . 0 0 % ( 0 / 1 5 1 5 ) 0 . 0 0 % ( 0 / 2 9 4 9 ) - - 4 - - - - - - - - 4 - - - - 4 - - A i

The copyright holder for this preprint 3  2  0  0  I  U  /  d  a  y   o  f  f  e  r   8  0  0  I  U  /  d  a  y   o  f  f  e  r   N  o  o  f  f  e  r  O  d  d  s  r  a  t  i  o  f  o  r   3  2  0  0  I  U  /  d  a  y  v  s  .  n  o   o  f  f  e  r  (  9  5  %  C  I  )   P  M  e  a  n  d  i  f  f  e  r  e  n  c  e   f  o  r  3  2  0  0  I  U  /  d  a  y   v  s  .  n  o  o  f  f  e  r  (  9  5  %   C  I  )   P  O  d  d  s  r  a  t  i  o  /  m  e  a  n   d  i  f  f  e  r  e  n  c  e  f  o  r  8  0  0   I  U  /  d  a  y  v  s  .  n  o   o  f  f  e  r  (  9  5  %  C  I  )   P  M  e  a  n  d  i  f  f  e  r  e  n  c  e   f  o  r  8  0  0  I  U  /  d  a  y  v  s  . n .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint for participants included in the intention-to-treat analysis, and B, for participants included in the sensitivity analysis excluding data from participants randomized to either intervention arm who reported that they took vitamin D capsules 'less than half the time' and those randomized to the no offer arm who reported any intake of supplemental vitamin D during follow-up. Bars show mean and standard deviation for each group. P values are from unpaired Student's t-tests.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.22.22271707 doi: medRxiv preprint

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

Vaccine hesitancy: the next challenge in the fight against COVID-19

SARS-CoV-2 evolution and vaccines: cause for concern?

Modulation of the Immune Response to Respiratory Viruses by Vitamin D

Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory

Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells

LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro

Molecular dynamics simulations and functional studies reveal that hBD-2 binds SARS-CoV-2 spike RBD and blocks viral entry into ACE2 expressing cells

Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli populationbased study

Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank

Habitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank

Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)

Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)

Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19

Symptom Study app

Infection and COVID-19 Clinical Outcomes

Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis

Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia

We thank all the people who participated in the trial; members of the Independent